European Press Release From Recordati SpA: RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS 06/19/2017 RECORDATI RARE DISEASES INC. ACQUIRES NORTH AMERICAN MARKETING RIGHTS TO CYSTADANE® (BETAINE ANHYDROUS FOR ORAL SOLUTION) 04/13/2017 RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER 08/16/2016 Pagination First page « First Previous page ‹ Previous … Page 12 Page 13 Current page 14 Page 15 Next page Next › Last page Last »
European Press Release From Recordati SpA: RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS 06/19/2017
RECORDATI RARE DISEASES INC. ACQUIRES NORTH AMERICAN MARKETING RIGHTS TO CYSTADANE® (BETAINE ANHYDROUS FOR ORAL SOLUTION) 04/13/2017
RECORDATI: ALBERTO RECORDATI APPOINTED CHAIRMAN; ANDREA RECORDATI APPOINTED VICE CHAIRMAN AND CHIEF EXECUTIVE OFFICER 08/16/2016
